Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 9/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29882694 | 1.00 | RORC (0.41) | RORCMAPKAPK2DGAT1ATRMALT1 | |
| SCHEMBL18839612 | 0.83 | MAPKAPK2 (0.41) | RORCMAPKAPK2ATR | |
| SCHEMBL23580455 | 0.82 | ACVRL1 (0.39) | RORCMALT1BRAFKDR | |
| SCHEMBL18862940 | 0.80 | MALT1 (0.40) | RORCMAPKAPK2ATRMALT1 | |
| SCHEMBL1010435 | 0.79 | ATR (0.46) | RORCMAPKAPK2ATR | |
| SCHEMBL5820080 | 0.78 | ATR (0.42) | RORCMAPKAPK2ATR | |
| SCHEMBL29813512 | 0.74 | ATF1 (0.42) | RORCMAPKAPK2ATR | |
| SCHEMBL23147986 | 0.74 | ATF1 (0.42) | RORCMAPKAPK2ATR | |
| SCHEMBL29813513 | 0.74 | ATF1 (0.42) | RORCMAPKAPK2ATR | |
| SCHEMBL6491966 | 0.74 | MAPKAPK2 (0.47) | RORCMAPKAPK2ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| CN-114945571-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2022-08-26 | — | — | CN | disclosed |
| WO-2021134004-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRODINGER, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | MALT1, FKBP1B, FKBP1A | RORC 623/4885MAPKAPK2 2040/4885DGAT1 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.